{"id":"NCT05349617","sponsor":"Bavarian Nordic","briefTitle":"Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years","officialTitle":"A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-05-12","primaryCompletion":"2023-06-19","completion":"2023-08-08","firstPosted":"2022-04-27","resultsPosted":"2024-12-13","lastUpdate":"2024-12-13"},"enrollment":413,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Chikungunya Virus"],"interventions":[{"type":"BIOLOGICAL","name":"CHIKV VLP/adjuvant","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1 - PXVX0317","type":"EXPERIMENTAL"},{"label":"Group 2 - Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.","primaryOutcome":{"measure":"Anti-CHIKV SNA Titer (NT80) Seroresponse Rates at Day 22 in Baseline Seronegative Participants","timeFrame":"21 days postvaccination","effectByArm":[{"arm":"Group 1 - PXVX0317","deltaMin":87.3,"sd":null},{"arm":"Group 2 - Placebo","deltaMin":1.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["40158524","35709798"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":206},"commonTop":["Myalgia","Fatigue","Headache","Injection Site Pain"]}}